Business Wire

NY-CITI-GLOBAL-WEALTH

9.12.2021 22:32:08 CET | Business Wire | Press release

Share
Citi Global Wealth Investments Releases Outlook 2022: The Expansion Will Endure: Seeking Sustained Returns

Citi Global Wealth Investments today released its Outlook 2022 report, titled The expansion will endure: Seeking sustained returns . Released twice yearly, Outlook provides in-depth insights into the global economy and financial markets for the year ahead and beyond, also highlighting transformational, multi-year “unstoppable trends” across markets.

The latest edition suggests that the strongest phase of the economic and market recovery from the pandemic is likely behind us. More normal conditions lie ahead following the “great rebound,” with more moderate returns as the equity bull market matures. But rather than leaving portfolios as they are, Citi believes this normalization calls for investors to make important asset allocation changes.

Going into 2021, Citi recommended positioning for a snapback in many assets that had been hit hardest by the pandemic. These included emerging markets, small-cap equities and beaten-down cyclicals. For 2022 and beyond, by contrast, Citi emphasizes exposure to “long-term leaders,” equities in high-quality companies in expanding industries that may deliver earnings growth in the long run. Historical analysis shows that long-term leaders have delivered strong returns with lower volatility over time. Examples include “dividend growers,” equities in companies with long records of increasing their dividends.

With inflation up but bond yields remaining low, Citi is reiterating the threat that negative real interest rates pose to wealth. “As we warned in last year’s report, the owners of cash and many bonds have suffered a loss of purchasing power in 2021,” said David Bailin, Chief Investment Officer and Head of Citi Global Wealth Investments . “We compare the effect of negative real rates to the activities of a cash thief, who we expect to remain at large in 2022. But we see various investments that may help clients preserve and grow purchasing power in the face of this threat.”

Citi has also identified “unstoppable trends” that are reshaping business and everyday life, as well as portfolios. These include multiple aspects of digitization such as cybersecurity, 5G and related technologies and fintech, as well as the ongoing shift of economic power towards Asia. In each of these areas, the pandemic has accelerated change. New working patterns, for example, are transforming the demand for offices, while the growth of online retail is intensifying the need for warehouse and delivery facilities.

“While we reiterate the importance of keeping portfolios positively positioned and fully invested, we also acknowledge a range of risks,” said Steven Wieting, Chief Investment Strategist and Chief Economist at Citi Global Wealth Investments . “The potential for vaccine-resistant COVID mutations, deteriorating U.S.-China relations, large-scale cyberattacks and evolving consumer spending habits based on inflation expectations all require close monitoring.”

With the economic expansion set to endure, we see the potential for further upside in financial markets. After a 45% rise in 2021, global earnings per share may increase by a more normal 8% in 2022. Global equities might deliver a mid-to-high single-digit return in this environment, with global fixed income returning 0% to 1% before inflation.

The full report, a summary version, short videos and other materials can be accessed here .

Announced in January 2021, Citi Global Wealth (“CGW”) is comprised of the wealth management businesses of Citi Private Bank and Citi’s Global Consumer Bank. Through these businesses, CGW delivers Citi’s wealth solutions, products and services globally. The unified management and delivery of CGW’s wealth strategy represents a further commitment by Citi to become a leading global wealth business. Citi Global Wealth Investments (“CGWI”) is comprised of the Investments and Capital Markets capabilities of Citi Private Bank, Citi Personal Wealth Management and International Personal Bank U.S.

About Citi:
Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management. Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release

Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye